GSK remains on fairly stable financial footing, with a debt/EBITDA ratio of 2.8 at the end of 2024 and Haleon taking on close to GBP 10 billion of GSK's debt in the 2022 divestment. With the improving ...

Pharma major GSK (LSE: GSK) on Tuesday said its urinary tract infection treatment gepotidacin, under the brand name Blujepa, ...

We recently compiled a list of the 12 Best ADR Stocks to Buy According to Hedge Funds. In this article, we are going to take ...

CureVac N.V. secured funding with GSK amid financial struggles, while a key patent win boosts stock. Click for why my ...

The four-pronged strategy begins with the acquisition of GSK's oncology portfolio, which includes all of its marketed products and late-stage candidates, for $14.5 billion, with a further $1.5 ...

GlaxoSmithKline (GSK) has firmly acquired the number one position in the Egyptian pharmaceutical market since 2009 and is likely to maintain the grip at least until the end of 2011. GSK’s ...

Haleon offers plenty of stability amidst the current market volatility, with its Power Brands driving strong organic growth.

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from ...

Dr. Salvadore is an established industry executive physician and leader with more than 15 years of experience leading ...

Gary Romano, M.D., Ph.D., to transition from Chief Medical Officer role-- SOUTH SAN FRANCISCO, Calif., March 28, 2025 (GLOBE NEWSWIRE) -- ...

AstraZeneca is making a $1bn investment for the long term, but what lies in store for investors over the next 12 months? Here ...